Corbus Pharmaceuticals
Presença
Corbus Pharmaceuticals é uma empresa listada sob o símbolo CRBP (US).
Executivos
Veja o organograma con seus 13 executivos principais
Biografias mais buscadas da Corbus Pharmaceuticals
- Yuval Cohen, Chief Executive Officer and Director
- Alan Holmer, Chairman of the Board
- Yong Ben, Director
Recentes movimentos de executivos em Corbus Pharmaceuticals
- Dominic Smethurst, ingressou na Companhia como Chief Medical Officer (Notícia publicada em 1 de março de 2024).
Criar um alerta
para seguir os movimentos de executivos da Corbus Pharmaceuticals.
Farmacêutica
Corbus Pharmaceuticals possui 1.860 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Johnson & Johnson (Estados Unidos).
Popular M&A news in Farmacêutica
- MedMen has filed for bankruptcy protection (publicado em 28 de abril de 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado em 23 de março de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado em 19 de março de 2024).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de Corbus Pharmaceuticals
- Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting
- Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC
- Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
- Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit
- Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer
- Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Corbus Pharmaceuticals Announces Proposed Public Offering
- Corbus Pharmaceuticals Announces Pricing of Public Offering
- Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
- CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024
- View more press releases Close
Redes sociais sobre Corbus Pharmaceuticals
- Corbus Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
- Corbus Pharmaceuticals na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Yuval Cohen 
Ligue para a Corbus Pharmaceuticals em +1 617...
